Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Sobi Eyes Japan Approval of 4 Rare Disease Drugs in 5 Years: Local Chief
December 12, 2023
-
REGULATORY Japan Reform Minister Calls for Roadmap to Eliminate “Switch Lags” in 3 Years
December 12, 2023
-
REGULATORY Japan Panel OKs Basic Plan for Elective Care Scheme for LLPs; 900 APIs Targeted
December 11, 2023
-
REGULATORY Will R&D Tax Credit Be Scaled Back with “Innovation Box” Rollout? Political Settlement Likely
December 8, 2023
-
REGULATORY Sawai’s Revlimid Generic, BMS’ AG Now Available; Trerief AG Launch Set for Feb. 20
December 8, 2023
-
REGULATORY First Generics for 5 APIs to Join NHI Price List; No Entries for Januvia, Zytiga
December 7, 2023
-
REGULATORY CEFP Discusses Social Security Reform Timeline, No Surprises for Pharma Measures
December 6, 2023
-
BUSINESS Pfizer to Cut Ties with 3 Regional Wholesalers, Further Narrowing Expected
December 5, 2023
-
REGULATORY Authorized Generics Cannot be Regulated Now but Must Be Watched Closely: MHLW Panel Members
December 5, 2023
-
REGULATORY Proposed Introduction of Elective Care Scheme for LLP Copay “Hard to Understand”: Chuikyo Members
December 4, 2023
-
REGULATORY Average NHI-Market Price Gap for 2024 Revision at 6.0%, Smallest in 30 Years
December 1, 2023
-
REGULATORY No Consensus on PMP Company Criteria, Likely Review for Spillover Rule: Chuikyo
November 30, 2023
-
BUSINESS Bayer Set to Continue Stepping Up External Collaborations to Develop New Drugs: Regional BD Chief
November 30, 2023
-
REGULATORY Pharma in Dogged Fight against Expansion of CEA Price Tweaks, Flags “Camel’s Nose”
November 29, 2023
-
BUSINESS UCB Japan Gathers Pace in Rare Disease Space with 2 New Launches for gMG
November 28, 2023
-
REGULATORY Meiji’s mRNA Vaccine, Pfizer’s RSV Vaccine Now in Line for Approval
November 28, 2023
-
REGULATORY Japan Deeping Debate on LLP Copay Review; Focus Is on Exclusion Criteria, Payment Levels, G1/G2 Rule Change
November 27, 2023
-
REGULATORY Chuikyo Reps Split on Nixing PMP Company Criteria; Many Back Review of Reduction Caps under Re-Pricing
November 24, 2023
-
BUSINESS Phesgo, Epkinly, Leqvio Hit Japan Market, Wegovy Launch Set for Feb. 22
November 24, 2023
-
BUSINESS BMS Japan Has Busy Years Ahead with String of Launches towards Doubling of Sales
November 22, 2023
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…